McKesson Corporation stock (US58155Q1031): Lifts annual profit forecast after Q4 earnings

McKesson Corporation raised its FY2027 profit guidance following strong Q4 2026 results, with shares up over 6% on the day of the announcement. The healthcare distributor highlighted focus on high-margin businesses.

McKesson Corporation, a leading U.S. pharmaceutical distributor, lifted its annual profit forecast on plans to prioritize high-margin businesses, as announced alongside its fiscal Q4 2026 earnings on May 7, 2026. The company reported revenue growth of 6.0% year-over-year for the quarter, according to its investor relations site as of May 7, 2026. Shares surged 6.31% to 741.02 USD on NYSE during trading on September 23, 2025, per MarketScreener as of September 23, 2025, amid broader market updates.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: McKesson Corporation
• Sector/industry: Pharmaceuticals distribution
• Headquarters/country: United States
• Core markets: U.S., Canada
• Key revenue drivers: Drug distribution, medical supplies
• Home exchange/listing venue: NYSE (MCK)
• Trading currency: USD

McKesson Corporation: core business model

McKesson Corporation operates as one of the largest healthcare companies in North America, focusing on pharmaceutical distribution, medical-surgical supplies, and healthcare technology solutions. The company serves pharmacies, hospitals, and physicians, distributing a wide range of brand-name and generic drugs. Its business model emphasizes efficient supply chain management and technology integration to support U.S. healthcare providers amid rising demand.

Through segments like U.S. Pharmaceutical and Specialty Solutions, McKesson handles billions in annual drug distribution volume. Fiscal Q4 2026 results highlighted resilience, with revenue up 6.0% from the prior year, as detailed in the May 7, 2026 earnings presentation on the IR site as of May 7, 2026.

Main revenue and product drivers for McKesson Corporation

McKesson derives most revenue from U.S. pharmaceutical distribution, which includes dispensing over 1 in 3 branded prescriptions in the U.S. Key drivers include specialty drugs for oncology and rare diseases, alongside medical supplies via its Supply Management business. The company set FY2027 EPS guidance at 43.800-44.600, signaling confidence post-Q4 beat.

Analyst forecasts show an average price target of 775.38 USD, implying 7.8% upside from recent levels around 719.30 USD as of July 3, 2025, per Zacks as of July 3, 2025. Institutional interest remains strong, with firms like HighPoint Advisor Group increasing holdings by 40.6% in Q4, per MarketBeat filings dated May 12, 2026.

Industry trends and competitive position

The U.S. pharmaceutical distribution sector faces margin pressures from drug pricing reforms but benefits from volume growth in specialty pharma. McKesson competes with AmerisourceBergen and Cardinal Health, holding a top-tier position with scale advantages. Its focus on high-margin areas like biopharma solutions positions it well for sector expansion projected through 2027.

Conclusion

McKesson Corporation's recent earnings and raised FY2027 guidance underscore its strategic shift toward higher-margin operations, driving share gains. With solid institutional backing and a key role in U.S. drug distribution, the stock reflects healthcare sector dynamics. Investors track upcoming catalysts like quarterly updates for sustained performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.